Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition by Johnson, Søren M. et al.
Research article
2528	 The	Journal	of	Clinical	Investigation	 	 	 http://www.jci.org	 	 	 Volume 120	 	 	 Number 7	 	 	 July 2010
Mitigation of hematologic radiation toxicity  
in mice through pharmacological quiescence 
induced by CDK4/6 inhibition
Søren M. Johnson,1,2 Chad D. Torrice,1,2 Jessica F. Bell,1,3 Kimberly B. Monahan,1,2 Qi Jiang,4  
Yong Wang,5 Matthew R. Ramsey,1,2 Jian Jin,6 Kwok-Kin Wong,7 Lishan Su,4  
Daohong Zhou,5 and Norman E. Sharpless1,2,8
1Department of Genetics, 2Department of Medicine, 3Department of Pediatrics, and 4Department of Microbiology and Immunology,  
The Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.  
5Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.  
6Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.  
7Department of Medicine, The Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. 8Department of Toxicology,  
















The cytotoxicity of DNA-damaging agents such as ionizing radia-
tion (IR) is cell cycle dependent. In particular, early G1 and late 
S phases are relatively radioresistant, whereas the G1/S transition 
and G2/M phases are relatively radiosensitive (1, 2). Traversing 
from G1 to S phase, while harboring DNA damage, is particularly 
toxic (3), and an extended period of G1 after exposure to genotox-
ins enhances resistance (4–6), possibly by allowing for greater DNA 
repair prior to G1/S traversal. We therefore reasoned that modu-
lating the cell cycle by lengthening G1 may mitigate the toxicity of 
DNA-damaging agents such as IR.
The transition from G1 to S phase is regulated by at least 3 cyclin-
dependent kinases (CDK2, CDK4, and CDK6) and their catalytic 
partner cyclins (cyclin A, cyclin D, and cyclin E), functioning in 
concert to phosphorylate the Rb family proteins (reviewed in ref. 7). 
Combinations of CDK-cyclin gene knockouts in mice have revealed 
considerable redundancy and/or developmental compensation 
among these proteins (reviewed in ref. 8). For example, murine 
embryos lacking both CDK4 and CDK6 or all the D-type cyclins 
demonstrate normal proliferation in many tissues but succumb 
late in development, due to a lack of fetal hematopoietic stem/pro-
genitor cells (HSPCs) (9, 10). Likewise, in adult mice, pharmacologic 
inhibition of CDK4/6 activity is well tolerated, only inhibiting pro-
liferation in a few CDK4/6-dependent cell types (11). Importantly, 
CDK2 and CDK1 phosphorylate several non-Rb substrates that reg-
ulate additional processes, such as transcription and DNA metabo-
lism (reviewed in ref. 12), whereas CDK4/6 are highly specific to Rb 
family proteins. Based on these observations, we hypothesized that 
we could improve resistance to DNA-damaging agents by inducing 
a G1 arrest using selective pharmacologic CDK4/6 inhibitors.
Results
To test this hypothesis in vitro, we first screened putative CDK4/6 
inhibitors for their cell cycle effects in several human cell lines. 
CDK4/6-dependent cell lines, including telomerized human diploid 
fibroblasts (tHDFs) and a human melanoma cell line (WM2664), 
demonstrated strong, reversible G1 arrest (pharmacological qui-
escence [PQ]) after exposure to the potent and selective CDK4/6 
inhibitors, PD0332991 (13, 14) and 2BrIC (15), whereas the less 
selective CDK inhibitors that additionally target CDK1/2 (roscovi-
tine [ref. 16], R547 [ref. 17], and flavopiridol [ref. 18]) variably pro-
duced a G2/M block, intra-S arrest, or cell death in these cell types 
(data not shown and Supplemental Figure 1; supplemental mate-
rial available online with this article; doi:10.1172/JCI41402DS1). 
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Effects of the nonselective CDK inhibitors were similar on an Rb-
null melanoma line, A2058, whereas the selective CDK4/6 inhibi-
tors had no effect on A2058 cell cycle or survival, even at doses 
well above the IC50 in CDK4/6-dependent cell lines (Supplemen-
tal Figure 1). The proliferation of 7 Rb-deficient human small cell 
lung cancer lines was also resistant to CDK4/6 inhibitors (data not 
shown), again reinforcing the notion that Rb-null cells are generally 
unaffected by CDK4/6 inhibition. These data show that structurally 
distinct, potent, and selective CDK4/6 inhibitors effect a “clean” G1 
arrest — without cytotoxicity, intra-S or G2 arrest — in susceptible 
cell lines, whereas the cell cycle effects of more global CDK inhibi-
tors are less predictable and associated with cytotoxicity.
Having identified 2 highly selective CDK4/6 inhibitors that elicit 
a clean G1 arrest in dependent cells, we next sought to determine 
whether PQ was protective from cell cycle–dependent genotoxic 
events in CDK4/6-dependent cell lines. IR exposure (Figure 1) 
and doxorubicin exposure (Figure 2) both caused extensive DNA 
damage (phospho–γ-H2AX foci and DNA strand breaks), elicited 
a robust DNA damage response (phospho-p53 and p21CIP expres-
sion), and caused cell death (WST-1 assay) in all 3 cell lines. Treat-
ment with PD0332991 or 2BrIC prior to genotoxic stress attenu-
ated γ-H2AX formation (Figure 1A, Figure 2B, and Supplemental 
Figure 2, A and B), DNA strand breaks (Figure 1C and Supplemen-
tal Figure 2C), and DNA damage response (Figure 1B, Figure 2C, 
and Supplemental Figure 2D) and promoted cellular survival in 
the CDK4/6-dependent cell lines WM2664 and tHDF (Figure 2D 
and Supplemental Figure 2E and Supplemental Figure 3A). Similar 
protection was observed after exposure to another DNA-damag-
ing agent, etoposide (data not shown). In contrast, no protective 
effects of PD0332991 or 2BrIC treatment were noted in Rb-defi-
cient A2058 cells (Figure 2D and Supplemental Figure 2E and 
Supplemental Figure 3A), and the less selective CDK inhibitors 
(roscovitine, flavopiridol, and R547) failed to enhance cell survival 
in any cell line (Supplemental Figure 3, B–D). The failure of the less 
selective inhibitors to afford protective 
PQ suggests that arrest in a phase of 
the cell cycle other than G1 (e.g., G2/M) 
may not protect from genotoxic expo-
sure. Alternatively, the less selective 
CDK inhibitors may prevent phosphor-
ylation of non-Rb family substrates by 
CDK2 (e.g., BRCA1 [ref. 19] or CtIP 
[ref. 20]) and thereby untowardly 
augment the toxicity of DNA-damag-
ing agents. Together, these data show 
that PQ, effected by selective CDK4/6 
inhibitors but not more global CDK 
inhibitors, provides in vitro resistance 
to DNA-damaging agents in cell types 
that require CDK4/6 kinase activity for 
G1 to S traversal.
To further test whether the protective 
effects of selective CDK4/6 inhibitors 
required the induction of G1 arrest, we 
performed cell synchronization experi-
ments. CDK4/6-dependent cells were 
released from CDK4/6 inhibition and 
allowed to progress to G2/M prior to 
doxorubicin exposure (Figure 2A, sche-
matic). Under such conditions, tHDFs 
and WM2664 cells demonstrated a marked increase in cellular toxic-
ity as measured by increased γ-H2AX foci, increased DNA damage 
response, and decreased cellular survival (Figure 2, B–D). Therefore, 
cells benefit from CDK4/6 inhibition only when it results in a G1 
arrest, and cells in G2 have enhanced sensitivity to DNA damage. 
This conclusion is supported by the observation that other means of 
promoting a G1 arrest (e.g., staurosporine treatment in certain cell 
types; ref. 21) can also enhance protection from genotoxic agents.
These in vitro data suggest that CDK4/6-dependent tissues 
in vivo might also be protected from DNA-damaging agents by 
CDK4/6 inhibitors. Motivated by prior work showing that fetal 
hematopoietic progenitors require CDK4/6–cyclin D for prolifera-
tion (9, 10) as well as the clinical need to protect the hematopoi-
etic system from DNA-damaging agents, we sought to determine 
whether hematopoietic progenitors could be rendered pharma-
cologically quiescent in vivo. Proliferation of murine HSCs (Lin–
Kit+Sca1+CD48–CD150+), as measured by Ki67 expression and 
incorporation of BrdU over 24 hours (Figure 3), was comparable to 
prior estimates (22, 23). When PD0332991, which is orally bioavail-
able, was administered for 48 hours prior to bone marrow harvest, 
the frequency of HSC proliferation decreased significantly (Figure 
3, B and C), with the greatest effect observed in Ki67 expression. An 
even more pronounced inhibition of proliferation was noted in the 
more rapidly proliferating multipotent progenitor (MPP) cell com-
partment (Lin–Kit+Sca1+CD48–CD150–). Oligopotent progenitors 
(Lin–Kit+Sca1–) demonstrated a modest inhibition of proliferation, 
with the strongest effects seen in common myeloid progenitors 
(CMPs) and common lymphocyte progenitors (CLPs), compared 
with weaker effects in the more differentiated granulocyte-mono-
cyte progenitors (GMPs) and megakaryocyte-erythroid progeni-
tors (MEPs; Figure 3, B and C). In contrast to these effects in early 
HSPCs, no change in proliferation was noted in the more fully dif-
ferentiated Lin–Kit–Sca1– and Lin+ cells, though these fractions are 
heterogeneous and effects on subpopulations may be obscured.
Figure 1
PQ enhances radioresistance in vitro. (A) Images of phospho–γ-H2AX foci (green) and phalloidin 
staining (red) of tHDFs, with or without 6 Gy IR and 24 hours of 100 nM PD0332991 exposure. 
Original magnification, ×40. Scale bar: 50 μm. (B) Western blots showing phospho-p53 (p-p53; 
arrow) induction in tHDF lysates after 6 Gy IR, with and without PD0332991 treatment. (C) Comet 
tail area, after 24 hours of exposure to 100 nM PD0332991, prior to the indicated IR dose. Forty 
cells in each condition were imaged at an original magnification of ×20. *P < 0.01, **P < 0.0001, for 
pair-wise comparisons.
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These effects on immunophenotypic HSPC frequency were 
validated by other methods. Transient (48-hour) treatment with 
PD0332991 did not decrease total marrow cellularity (Supplemen-
tal Figure 4A) but did decrease the absolute number of lineage-nega-
tive cells (Figure 3D) without altering HSPC apoptosis or viability 
(Supplemental Figure 4, B and C). The frequency of the more abun-
dant oligopotent progenitors declined (Lin–cKit+Sca1–; Figure 3D 
and Supplemental Figure 4D), with an associated relative increase in 
HSC and MPP frequencies. Cobblestone area–forming cell (CAFC) 
assays confirmed that transient CDK4/6 inhibition did not decrease 
the in vivo HSPC number (Supplemental Figure 4E). In combina-
tion, these data suggest a gradient of dependence on CDK4/6 activ-
ity for proliferation during myeloid/erythroid differentiation: the 
least differentiated cells (HSCs, MPPs, and CMPs) appeared to be 
the most dependent, more differentiated elements (GMPs and 
MEPs) were less dependent, and even more differentiated myeloid 
and erythroid cells proliferated independently of CDK4/6 activity.
In accordance with this model, serial daily treatment with 
PD0332991 for 12 days caused a modest decrease in the erythroid, 
platelet, and myeloid (monocyte and granulocyte) lineages, which 
only became apparent after 8 days of treatment, and which began 
to improve within 4 days, 
upon cessation of PD0332991 
(Supplemental Figure 5). 
These observations are con-
sistent with the kinetics and 
degree of myelosuppression 
seen when tumor-bearing mice 
(11) and human patients with 
malignancies (24, 25) are seri-
ally treated with PD0332991. 
These data confirm that the 
short-term production of dif-
ferentiated peripheral blood 
effector cells is relatively resis-
tant to CDK4/6 inhibition 
and that the myelosuppressive 
effects of CDK4/6 inhibition 
are rapidly reversible in vivo.
Given that PQ affords cellu-
lar protection in vitro (Figures 
1 and 2) and effects a specific 
G1 arrest of HSPCs in vivo 
(Figure 3), we next sought to 
test whether CDK4/6 inhibi-
tion would render wild-type 
mice resistant to the hemato-
logical toxicity of total body 
irradiation (TBI), administered 
at doses around the LD90 (7.5 
Gy). Adult female C57BL/6 
mice were exposed to 6.5, 7.5, 
or 8.5 Gy, with or without 
PD0332991 treatment (admin-
istered as shown in Figure 4A), 
and followed for 40 days after 
TBI. Marked protection from 
the hematological toxicity of 
peri-lethal doses of TBI was 
observed. Nearly all untreated 
mice succumbed to death from hematological toxicity when 
exposed to 7.5 Gy, whereas all treated mice survived (Figure 4B). 
At 8.5 Gy TBI, PD0332991 treatment significantly increased the 
30-day survival (13% treated vs. 0% untreated mice) and prolonged 
the median survival (19 days for treated vs. 13 days for untreated; 
Supplemental Figure 6A). All mice survived after a dose of 6.5 Gy, 
regardless of PD0332991 treatment (Supplemental Figure 6B). 
These data show that PQ resulting from transient CDK4/6 inhibi-
tion around the time of TBI enhances radioresistance in vivo.
Because 3 doses of PD0332991 at different times relative to TBI 
provided radioprotection, we next sought to determine which of 
these doses was most important for radioprotection. We observed 
that most of the benefit of the treatment schedule was associated 
with CDK4/6 inhibitor treatment immediately prior to or simulta-
neous with TBI at the LD90. Mice treated with a single dose 4 hours 
before or a single dose at TBI (time 0) demonstrated survival similar 
to that of animals treated on the multidose schedule (doses at 28 
and 4 hours before TBI and 20 hours after TBI) (Figure 4, B and C). 
The benefit of treatment at 4 hours prior to TBI was confirmed in 
a larger cohort of mice (n = 62), including matched animals from 
3 different inbred strains (C57BL/6, C3H, and FVB/n) and both 
Figure 2
PQ enhances radioresistance in vitro. (A) An in vitro schedule of CDK inhibitor (CDKi) and doxorubicin (Dox) 
exposure using tHDFs. Assays were performed where indicated on the timeline with arrows. WB, Western 
blot. (B) Flow cytometry analysis of phospho–γ-H2AX formation after PD0332991 and doxorubicin treatment 
of tHDFs. (C) Western blot analysis of DNA damage response markers in tHDFs, at indicated times after 
PD0332991 treatment, with or without doxorubicin treatment. The black bar indicates lysates harvested 
immediately after IR exposure (t = 0 hours), and the gray bar indicates lysates harvested 12 hours after IR 
exposure (t = 12 hours). (D) WST assay for cell proliferation at 7 days after doxorubicin exposure. All absor-
bances are normalized to DMSO. #P < 0.01 vs. DMSO, ##P < 0.001 vs. DMSO, *P < 0.01 vs. doxorubicin, 
**P < 0.001 vs. doxorubicin, ***P < 0.0001, for the indicated pair-wise comparisons. “Wash” indicates time in 
media without CDK inhibitor or doxorubicin, as shown in A.
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male and female mice (Figure 4D). Surprisingly, even a single dose 
20 hours after TBI significantly enhanced survival after TBI (Fig-
ure 4C). As therapeutic serum levels are not achieved until more 
than 30 minutes after gavage and then persist for 10–20 hours 
(data not shown), these observations suggest that a period of PQ 
lasting for several hours (>20 hours) after the induction of DNA 
damage is beneficial. Although there are a few known compounds 
that protect from radiotoxicity when administered prior to IR (i.e., 
“radioprotectants”) (26, 27), we are unaware of any hematological 
“radiomitigants,” (i.e., compounds that reduce myelotoxicity when 
administered many hours after an exposure to TBI).
TBI at doses used in this study causes morbid pancytopenia, with 
count nadirs occurring 14–21 days after TBI (28). To confirm that 
the improved survival afforded by PQ was due to protection of hema-
topoietic lineages, we examined the bone marrow and peripheral 
blood of animals after IR exposure. We observed a marked reduction 
of caspase activity in bone marrow mononuclear cells (BM-MNCs) 
harvested 16 hours after TBI from mice that had been pretreated 
with PD0332991 prior to TBI (Figure 4E). In accordance with this 
protection observed in the bone marrow after TBI, we also observed 
that PD0332991 treatment significantly ameliorated pancytopenia 
in lethally irradiated mice (Figure 4F). A similar improvement of 
cell count nadirs and more rapid cell count recovery was observed 
after a sublethal dose of TBI (Supplemental Figure 7). Importantly, 
PQ therapy had a beneficial effect on the recovery of all peripheral 
blood lineages: platelets, erythrocytes, myeloid cells (granulocytes 
and monocytes), and peripheral lymphocytes. The improvement in 
quadrilineage hematopoiesis after TBI is consistent with the notion 
that CDK4/6 inhibition exerts maximal radioprotection in the early 
HSPCs rendered quiescent by CDK4/6 inhibitor treatment.
In order to bolster these pharmacologic data, we next turned to a 
genetic model. Prior work in mice has shown that p21CIP, a potent 
CDK inhibitor and critical mediator of the p53-mediated DNA dam-
age response (29, 30), plays an important role in regulating HSPC 
quiescence after DNA damage (31). To test the importance of p21CIP 
in hematologic radiomitigation, we exposed inbred p21CIP-null, 
heterozygous, and wild-type littermates to lethal TBI, both with-
out (Figure 5A) and with (Figure 5B) PD0332991. For these experi-
ments, an x-ray IR source was used at a dose greater than the LD90. 
Confirming the critical role of p21CIP in mediating cellular survival 
after IR, survival after TBI strongly correlated with p21CIP gene dos-
age: p21CIP-null animals were most sensitive, while wild-type animals 
Figure 3
CDK4/6 inhibition decreases HSPC proliferation. (A) Flow cytometry gating scheme for HSCs and MPPs (top) and myeloid progenitors (bottom) 
using cell surface antigens. Gray regions represent cell populations used for further analysis as indicated. FSc, forward scatter. (B) Represen-
tative contour plots of proliferation in indicated HSPC populations, as measured by BrdU incorporation and Ki67 expression, after 48 hours of 
no treatment (n = 6) or PD0332991 treatment (n = 6) in the presence of BrdU for 24 hours. Contours represent 5% density. (C) Quantification 
of BrdU and Ki67 data in all HSPC subpopulations. (D) Relative frequency of Lin–, HSC, MPP, or Lin–cKit+ Sca1– populations after 48 hours of 
PD0332991 treatment and 24 hours of BrdU exposure. *P < 0.05, **P < 0.01, ***P < 0.001.
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were most resistant, and heterozygotes were intermediate (Figure 
5A). Administration of PD0332991 4 hours prior to TBI improved 
survival in all 3 genotypes, but PD0332991 treatment did not fully 
rescue the radiosensitivity of p21CIP-null mice (Figure 5B). These 
observations are in accordance with PQ data (Figure 4C), suggesting 
that the induction of a cell cycle pause well after the onset of DNA 
damage improves HSPC survival. Moreover, the beneficial effects of 
PQ after TBI do not strictly require p21CIP, although expression of 
this CDK inhibitor appeared to enhance the effects of PQ.
Prior work has suggested that some radioprotectant strategies 
are associated with an increased late risk of leukemia (32), pre-
sumably resulting from an augmented survival of damaged cells 
after IR. To assess the risk of late toxicity, we serially examined 
mice after TBI in the presence or absence of PQ. When followed 
210–274 days after TBI, no deaths were seen in any animals after 
6.5 Gy TBI, regardless of PD0332991 treatment. Only 2 out of 18 
mice (1 C3H and 1 C57BL/6) survived 7.5 Gy TBI in the absence of 
PQ, and these animals showed no evidence of disease 143–252 days 
after TBI. Of 29 mice surviving the acute toxicity of 7.5 Gy TBI in 
the setting of PQ, there was 1 death of unknown cause at day 99 
after TBI, and the remaining mice were disease free 101–251 days 
after TBI. Blood counts of long-term–surviving animals were com-
parable among unirradiated and irradiated mice, with or without 
PD0332991 treatment, at the time of TBI (Supplemental Figure 8). 
No evidence of myeloproliferative disorder or myelodysplasia was 
seen in animals of these long-term–surviving cohorts. These data 
indicate that PQ does not exacerbate the late hematological tox-
icity associated with sublethal TBI and affords good long-term 
hematological radioprotection, even after a lethal dose of TBI.
Although these results demonstrate the ability of PQ to reduce 
the toxicity of DNA-damaging agents, exposure to IR and other 
DNA-damaging agents more commonly occurs therapeutically in 
the treatment of cancer. To determine whether PQ could protect the 
bone marrow of a tumor-bearing host without also protecting its 
cancer, we examined the effects of PQ on tumor response in a well-
defined, genetically engineered murine model of melanoma (33). In 
this model, male TyrRas Ink4a/Arf–/– mice develop autochthonous 
melanomas, driven by melanocyte-specific expression of mutant 
Figure 4
PQ at the time of TBI increases survival. (A) The PD0332991 treatment schedule in initial radioprotection experiments. The arrows indicate doses 
of PD0332991 before or after TBI (shown as lightning bolt). (B) Kaplan-Meier analysis of survival after 7.5 Gy of TBI, with or without PD0332991 
treatment. (C) Survival after 7.5 Gy TBI, with the indicated dosing schedules of PD0332991. (D) Aggregate results of animals gavaged 4 hours 
prior to TBI, representing results from 3 murine strains with animals of both sexes. Results of strains considered independently were comparable 
in all groups (see Figure 6C and Supplemental Figure 6C). All survival curve P values were calculated using the log-rank test as a pair-wise 
comparison with the untreated group. (E) Caspase activation in BM-MNCs after exposure to 7.5 Gy TBI (x-rays; see Methods). (F) Complete 
blood counts with differential at 21 days after 7.5 Gy TBI, with and without PD0332991 treatment. Treated animals received PD0332991 by oral 
gavage at 28 and 4 hours prior to (–28 and –4, respectively) and 20 hours after (+20) IR dose on day 0. Myeloid cells include granulocytes and 
monocytes, and # indicates that the maximum value of the cohort is shown in lieu of error bars where cells numbers were too small to reliably 
quantify. *P < 0.05, **P < 0.01, ***P < 0.001. 
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H-Ras in the setting of combined p16INK4a and Arf inactivation (Fig-
ure 6A). Even though development of these tumors is facilitated by 
loss of p16INK4a (34), a potent CDK4/6 inhibitor, their growth was not 
inhibited by serial CDK4/6 inhibitor treatment (Figure 6B), suggest-
ing established tumors in this model do not require CDK4/6 activity 
for continued proliferation. Moreover, these tumors are sensitive to 
IR, with 7.5 Gy TBI arresting tumor growth for approximately 20 
days after IR, whereas all unirradiated tumors demonstrated overt 
progression within 10 days (Figure 6B). However, when tumor-bear-
ing mice were treated with a single dose of PD0332991 4 hours prior 
to TBI, an impressive rescue of radiation-induced morbidity, in terms 
of weight loss (Supplemental Figure 9B) and mortality (Figure 6C), 
was seen without a change in tumor response (Figure 6, B and C). 
These data reveal that PQ can reduce treatment-associated myelo-
suppression after exposure to DNA-damaging agents, without con-
comitantly protecting an established, CDK4/6-independent cancer.
Discussion
The cell cycle phase has long been linked to cellular radiosensitivity 
(1, 2), and attempts to modify radiosensitivity through manipula-
tion of the cell cycle were originally described several decades ago 
(35, 36). The approach described in the present work adds speci-
ficity for HSPCs through selective pharmacologic inhibition of 
CDK4/6. Our data demonstrate that such inhibition induced a G1 
arrest in CDK4/6-dependent cells (Supplemental Figure 1), thereby 
protecting such cells from genotoxins. In contrast, cells that did 
not require CDK4/6 activity for proliferation were not arrested by 
CDK4/6 inhibitors and were not protected by such agents (Fig-
ures 1 and 2). Likewise, less selective CDK inhibitors that target 
CDK1/2, among other kinases, did not induce a clean G1 arrest in 
vitro and did not afford protection from DNA-damaging agents. 
If anything, in our studies, nonselective CDK inhibitors appear to 
augment the toxicity of DNA-damaging agents, in accordance with 
prior work from several other groups (20, 37, 38).
Although the precise mechanism(s) by which an augmented G1 
arrest protects cells from IR cytotoxicity is not well understood, 
our data support a few possible explanations. We show that cells 
arrested in G1 demonstrate an increased resistance to the DNA-
damaging effects of IR (Figure 1). Other groups have reported an 
intrinsic resistance to DNA-damaging agents in G1 as well as an 
augmented rate of DNA repair in this phase of the cell cycle (39, 
40). A reduced susceptibility to IR-induced DNA damage in G1 
could partially explain the radioprotection we observed; however, 
such an explanation cannot account for the radiomitigation effects 
of PQ in vivo, where G1 arrest after IR exposure is protective.
Prevention of G1 to S traversal is an alternative mechanism that 
can explain the radiomitigation effects of CDK4/6 inhibitors. 
Attempted G1 to S traversal, in the setting of unrepaired DNA dam-
age, is a particularly toxic event (3, 41), likely due to activation of 
early S phase transcription factors, such as the E2Fs, which regulate 
many effectors of apoptosis (42, 43). This mechanism is consistent 
with increased radiosensitivity noted in late G1 (1, 2), more recently 
described as damage occurring after the G1 restriction point (44, 
45). Additionally, it may be that certain types of IR-induced lesions 
(single-strand breaks [SSBs] or more rarely interstrand crosslinks 
[ISCLs]) are relatively nontoxic in G1 (46) but become more toxic in 
S phase, as these lesions are converted to toxic DSBs (e.g., through 
stalled replication forks). Indeed, although DSBs are highly corre-
lated with cytotoxicity, approximately 90% of DNA lesions after IR 
are SSBs (47), while ISCLs may also be induced at lower frequency 
by IR (48). Therefore, inhibiting G1 to S traversal may be beneficial, 
by preventing apoptosis associated with E2F induction or by allow-
ing time for repair of lesions that are well tolerated during G1, but 
which may be converted to more toxic DSBs during S phase.
We believe prevention of G1 to S traversal explains how selective 
CDK4/6 inhibitors improve survival when administered concur-
rent with or up to 20 hours after exposure to lethal IR (Figure 4C). 
This mechanism is additionally supported by the requirement for 
induction of p21CIP for optimal survival after IR (Figure 5). Expres-
sion of p21CIP peaks 24–48 hours after IR exposure (49), and mice 
lacking p21CIP are sensitive to the hematologic toxicities of IR (Fig-
ure 5). Therefore, a cell cycle pause induced by p21CIP hours after 
IR ameliorates the hematopoietic toxicity of IR. Additional sup-
port for this view is provided by the recent finding that FBXO31 
expression is required for maximal radioprotection after IR (50). 
Like p21CIP, FBXO31 expression is induced hours after IR in an 
ATM-dependent manner, and its expression induces degradation 
of cyclin D1, thereby reducing CDK4/6 activity and inducing a G1 
arrest in some cell types. Therefore, a maximal G1 arrest effected 
by disparate mechanisms after IR appears beneficial for survival. 
Additionally, the G1 arrest induced in HSPCs by antiproliferative 
mechanisms, like p21CIP, after IR does not appear complete, in that 
it can be further enhanced by PQ (Figure 5).
Current clinical interventions to mitigate radiation toxicity have 
relied on a combination of supportive care, growth factors, cytokines, 
and specific chelating agents — none of which are effective when 
administered several hours after radiation exposure (reviewed in ref. 
27). While growth factor support with agents such as G/GM-CSF or 
erythropoietin has been shown to attenuate the toxic effects of DNA-
damaging agents (32, 51), the small molecule PQ approach appears 
superior in magnitude of effect, has a longer effective duration after 
exposure, and protects without the significant expense and toxicities 
of these biologics. Small molecule CDK4/6 inhibitors are orally bio-
available and can be readily stockpiled, both highly desirable features 
for agents to be used in the setting of a radiologic disaster. Moreover, 
PQ ameliorates DNA damage–induced thrombocytopenia (Figure 4F 
Figure 5
Cell cycle arrest after lethal TBI improves 
survival and requires both p21CIP and 
CDK4/6 inhibition for optimal benefit. 
Kaplan-Meier survival curves for wild-
type, heterozygous, and p21CIP-null 
mice, exposed to lethal TBI 4 hours 
after oral gavage with (A) vehicle or (B) 
PD0332991. Mice were irradiated using 
an x-ray source (see Methods). The log-
rank test for trend is shown.
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and Supplemental Figure 7), a significant, unmet need in clinical 
oncology and radiation mitigation. While late hematological toxic-
ity has been associated with growth factor support after exposure 
to DNA-damaging agents in both humans (52, 53) and mice (32), 
PQ does not appear to augment late hematological toxicity after 
TBI (Supplemental Figure 8). Furthermore, growth factor support 
and PQ appear to enhance count recovery through different mecha-
nisms: the former by inhibiting apoptosis, increasing HSPC prolifer-
ation, and modulating lineage choice; the latter by promoting DNA 
repair prior to a resumption of progenitor proliferation. Therefore, 
we think it likely that the combined use of PQ and growth factor 
support may prove particularly beneficial in ameliorating myelosup-
pression resulting from the exposure to DNA-damaging agents.
In addition to providing radiomitigation, PQ could also be used 
as an adjuvant to clinical anticancer therapy. Although cell cycle 
alteration has successfully improved survival from lethal IR in the 
past (35, 36), prior strategies possessed limited clinical utility due to 
the lack of selective alteration of the cell cycle in the bone marrow 
without affecting tumors. The PQ approach capitalizes upon the 
relatively infrequent requirement for CDK4/6 activity for tumor 
maintenance in order to selectively radioprotect hematopoietic 
progenitors (Figure 4, E and F), thereby improving survival after IR 
without compromising tumor cell kill (Figure 6, B and C). Prevent-
ing myelosuppression after cytotoxic cancer therapies would allow 
increased dose intensity and density, allowing increased tumor 
cell kill. However, our data do suggest that PQ would compromise 
tumor cell kill in cancers that are sensitive to CDK4/6 inhibition, 
although we believe this concern would not apply to most human 
malignancies. For example, CDK4/6 inhibitors failed to induce G1 
arrest in Rb-deficient small cell lung cancer cell lines, and therefore 
PQ would be unlikely to compromise chemotherapeutic efficacy in 
the approximately 10% of human cancers that are Rb deficient. A 
similar logic applies to cancers with other genetic lesions that ren-
der them insensitive to CDK4/6 inhibition (e.g., Myc activation). 
Importantly, even some tumors (e.g., TyrRas Ink4a/Arf–/– melano-
ma) whose progression is facilitated by inactivation of p16INK4a, 
an endogenous CDK4/6 inhibitor, were not protected by CDK4/6 
inhibitors at the time of IR exposure (Figure 6B). Therefore, it is 
likely that PQ could attenuate the hematological toxicity of anti-
cancer therapies in a substantial fraction of human cancer patients 
without a concomitant diminution in anticancer efficacy.
CDK4/6 inhibitors are in an advanced stage of clinical development 
as antineoplastics. PD0332991 has been administered to humans (24, 
25), and 5 current phase I/II trials with this compound are planned or 
underway testing (listed at http://clinicaltrials.gov/ as NCT00555906, 
NCT00420056, NCT00721409, NCT00141297, and NCT01037790). 
Several other series of selective CDK4/6 inhibitors have been reported 
(54), with at least 2 additional candidates slated to soon enter human 
phase I trials. Therefore, we believe the ready availability of these rela-
tively nontoxic, small molecule inhibitors with favorable pharmacol-
ogy in humans will allow for human testing of the beneficial effects of 
PQ after TBI and DNA-damaging agents in short order.
Methods
Animals. All animal experiments were performed with approval of the Uni-
versity of North Carolina Institutional Animal Care and Use Committee. For 
Figure 6
CDK4/6 inhibition improves survival without compromising tumor sensitivity to radiation therapy. (A) Representative images of the progression 
of an autochthonous TyrRas Ink4a/Arf–/– melanoma, despite daily oral therapy with PD0332991. (B) Tumor growth with or without continuous 
daily PD0332991 treatment compared with tumor growth with or without PD0332991 administered as a single dose 4 hours prior to 7.5 Gy TBI. 
“NS” is nonsignificant for the comparison between groups receiving 7.5 Gy TBI. (C) Kaplan-Meier survival curves showing overall mortality and 
mortality subdivided by cause. P values were calculated using the log-rank test.
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studies of wild-type mice, young adult (8–12 weeks of age) C57BL/6 (The 
Jackson Laboratory) or C3H (Harlan Sprague-Dawley) animals were used. 
TyrRas Ink4a/Arf–/– mice were FVB/n background, and p21CIP–/– mice were 
obtained from Hanno Hock (Massachusetts General Hospital, Boston, Mas-
sachusetts, USA) and then fully backcrossed (n = 10 generations) to C57BL/6 
for study. Peripheral blood was collected by tail vein nick for complete blood 
counts (HemaTrue, Heska). Experiments on tumor-bearing TyrRAS+ Ink4a/
Arf–/– mice (33) were performed in males fully backcrossed (n > 10) to the 
FVB/n background. Mice were treated as previously described (11) with 
PD0332991 (Pfizer Inc.), given by oral gavage at a dose of 150 mg/kg BW. Tyr-
RAS+ Ink4a/Arf–/– mice were serially observed for tumor development. When 
tumors were noted to be approximately 0.2 cm2 in size, animals were treated 
as described and tumor response was assessed by daily caliper measurements. 
Data in Figure 6B are normalized to tumor size at the time of therapy initia-
tion, with volumes calculated using the formula (width × length)2/2. Tumor-
bearing mice were euthanized at the indicated times for morbidity, tumor 
ulceration, or tumor size of more than 1.5 cm in diameter.
IR sources. Animals were irradiated using a 137Cs AECL GammaCell 40 
Irradiator (Atomic Energy of Canada) or a XRAD320 (Precision XRay Inc.) 
biological irradiator. Experiments were carried out using the 137Cs source, 
unless otherwise noted. Our empirically determined LD90 in this system 
was 7.5 Gy, consistent with prior studies (28, 32, 51, 55).
Cell lines, γ-H2AX by flow cytometry, WST-1, and Western blots. tHDFs (from 
Gordon Peters, London Research Institute, London, United Kingdom) were 
cultured in DMEM plus 10% FBS with any additional compounds. The same 
conditions were used for A2058 and WM2664, human melanoma cell lines 
with known Rb-pathway mutations: A2058 is Rb-null, whereas WM2664 lacks 
Ink4a/Arf (56). For γ-H2AX assay, cells were fixed, permeabilized, and stained 
with anti–γ-H2AX as per the γ-H2AX Flow Kit (Millipore). Cell viability was 
assessed using a colorimetric assay for cleavage of water soluble tetrazolium 
salt (WST-1 assay; TaKaRa Bio USA), performed by seeding 1 × 103 cells per 
well in a 96-well tissue culture plate in 100 μl of growth medium and treating 
as indicated with CDK4/6 inhibitor (100 nM PD0332991 or 2 μM 2BrIC) and 
radiomimetic (1 μM doxorubicin). Following treatment, cells were allowed to 
recover for 7 days in normal growth medium, and then the cell number was 
quantified using the WST-1 assay. For cell number and viability, as measured 
by CellTiter-Glo Luminescent Cell Viability Assay (Promega), cells were seeded 
overnight, incubated for 16 hours with CDK4/6 inhibitor, and next incubated 
for 8 hours with CDK4/6 inhibitor and doxorubicin. Fresh media was then 
added, and cell number and viability were quantified 5 days later. γ-H2AX 
levels were assessed by flow cytometry after fixation and anti–γ-H2AX–FITC 
incubation (Millipore). Western blots were performed on cell lysates in NP-40 
lysis buffer with protease inhibitors (Roche) and phosphatase inhibitors (Cal-
biochem) as previously described (11), using anti–p53-phospho-Ser15 (Cell 
Signaling), Bax, and actin-HRP (Santa Cruz Biotechnology Inc.).
Comet tail assay after IR. tHDFs received 6 Gy IR from a RS2000 Biological 
Irradiator (RadSource Inc.), with or without 24 hours of prior exposure 
to 100 nM PD0332991. Cells were placed on ice 5 minutes after IR and 
processed, as previously described (57), prior to electrophoresis with SYBR 
Green (Applied Biosystems), imaged as for γ-H2AX (see below), and quanti-
fied using Comet Score software (TriTek Co.).
γ-H2AX and clonogenic assay after IR. For γ-H2AX images, tHDFs received 6 
Gy IR, with or without 24 hours of prior exposure to 100 nM PD0332991. 
Five minutes after IR, cell were washed twice with ice-cold PBS, fixed with 
4% paraformaldehyde plus 0.1% Triton-X (Sigma-Aldrich) for 30 min-
utes, washed twice with ice-cold PBS, incubated with anti–γ-H2AX–Alexa 
Fluor 488 (Cell Signaling) and phalloidin–Alexa Fluor 568 (Invitrogen) for 
1 hour, washed 4 times with ice-cold PBS, and mounted. Images were cap-
tured using a mercury laser attached to an inverted microscope (model 
IX-81, Olympus), which was equipped with a ×20 or a ×40 PlanApo objec-
tive and a CCD camera (model C4742-80-12AG, OCAR-ER, Hamamatsu), 
which was controlled by Slidebook software. Mean nuclear intensities were 
computed using ImageJ software (http://rsbweb.nih.gov/ij/). The clono-
genic assay was performed as previously described (58), with cells plated 
in a 6-well plate 6 hours prior to treatment for 24 hours with 100 nM 
PD0332991, with 6 Gy IR occurring 12 hours after drug exposure.
Compounds. R547 (17) was synthesized by the Center for Integrative 
Chemical Biology and Drug Discovery (CICBDD). 2BrIC was synthe-
sized by OTAVA Chemicals, based on compound 4d, as shown in ref. 15. 
PD0332991 (13, 14) was provided by Pfizer Inc. or synthesized by the 
CICBDD. Flavopiridol (18) was purchased from Sigma-Aldrich. Roscovi-
tine (16) was purchased from LC Laboratories.
BM-MNC isolation and CAFC assay. BM-MNC isolation and CAFC assays 
were performed as previously described (59). Briefly, bone marrow was 
harvested from femurs and tibias of mice and centrifuged to purify BM-
MNCs. The frequencies of CAFCs were determined at weekly intervals 
(on day 7, 14, and 35). Wells were scored positive if at least 1 phase-dark 
hematopoietic clone (containing 5 or more cells) was seen. The frequency 
of CAFCs was then calculated using L-Calc software (StemCell Technolo-
gies) for limiting dilution analysis.
Bone marrow immunophenotyping and proliferation by flow cytometry. For 
HSPC proliferation experiments, mice received daily oral gavage with 
PD0332991 for 2 days, with an intraperitoneal injection of 1 mg BrdU 
every 6 hours for 24 hours prior to sacrifice. BM-MNC harvest and immu-
nophenotyping was performed using rbc lysis, biotin-conjugated Lin-panel 
incubation (Invitrogen), paramagnetic bead-conjugated streptavidin (Milt-
enyi Biotec) incubation, and magnetic depletion, using an AutoMACS 
(Miltenyi Biotec). At least 2 × 106 Lin-depleted cells per mouse were incu-
bated with fluorescently labeled antibodies against cell surface antigens 
used to identify hematopoietic progenitor subpopulations, as previously 
described (23, 60): CD34-FITC, CD16/32–Pacific Blue, IL7Ra-PE-Cy5, and 
cKit-APC–Alexa Fluor 750 from eBiosciences; Sca1-PE-Cy7, CD150-PE-Cy5, 
and CD48–Pacific Blue from BioLegend; and Aqua Live/Dead viability dye 
(Invitrogen). Streptavidin-PE–Texas Red (Invitrogen) was used to confirm 
efficiency of lineage depletion (data not shown). After cell surface staining, 
cells were fixed, permeabilized, and stained with antibodies against Ki67-
FITC, BrdU-APC, and caspase3-PE (BD Biosciences). In all experiments, 
gating based on isotype controls was used as appropriate (data not shown). 
Flow cytometry was performed using a CyAn ADP (Dako) and analyzed 
with FlowJo software (Tree Star). For each bone marrow sample, a mini-
mum of 200,000 cells were analyzed using FlowJo software (Tree Star). For 
cell culture samples, a minimum of 20,000 cells were analyzed.
Statistics. Unless otherwise noted, comparisons are made with 1-way 
ANOVA, with Bonferroni correction for multiple comparisons where 
appropriate. P values of less than 0.05 are considered significant. Error 
bars represent ± SEM.
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